Preproposal Call Earlier recognition of cardiovascular diseases.
Deadline September 14 th 2015, 14:00 hours
I General information max 1 A4
1. Title (incl. acronym if applicable)
2. Applying for part A or part B?
3. Abstract (max 350 words)
4. Contact information of the Applicant (please attach a short Curriculum Vitae of the applicant, max 1 A4
(using template, see below))
Name
Name organization
Email address
5. Contact information of the participating Principal Investigators/co-applicants
(please attach a short Curriculum Vitae of each participating investigator, max 1 A4 (using template, see
below))
Name
Name organization
6. Duration (max 5 years)
7. Amount requested (max 950 K EUR)
8. Keywords (max. 5)
e-mail address
Preproposal call 2015 earlier recognition of cardiovascular disease
II Short Description: max 3 A4
1. Healthcare problem
a. Which cardiovascular healthcare problem (suitable within this programme) must be solved?
b. How does the project fits the scope of this programme?
2. Objectives of the project
3. Excellence/ innovative aspects
4. Concise description of the planned research
5. Expected results, at least a description should be given of:
a. the expected results in relation to the healthcare problem and,
b. the implementation thereof in clinic and industry.
6. . Impact
a. Application perspective (Describe here the economic and/or societal relevance and the possible
impact of the research project for specifically the Netherlands as well as internationally. Please also
state which results the users can expect immediately after the project, in how many years nonscientific applications can be realised and what the market for these is. What do you need for a broad
implementation?)
b. Utilisation plan (The utilisation plan must be clear for people without specific prior knowledge. Outline
according to a step-by-step plan (during and after the project) how you will ensure that the research
results are actually applied by users. State the expected obstacles to using the research results, for
example due to IP or legislation.
7. . Preliminary patent search results: 'freedom to operate' is essential here, i.e. no infringement on existing
property rights of third parties.
8. Only is applying for part A: IP policy (see page 29 of the brochure): Please indicate for which option you
intend to choose:
1. follow STW policy
2. making own arrangements
III Consortium: max ½ A4
1. Expertise of the researchers involved
2. Interaction between disciplines
3. Embedding
4. User community (State here the intended user group and their commitment to the research. State the
breadth of the users' community that will apply the results from the programme. Clearly state how all
aspects of possible applications of the results are sufficiently covered with a relevant user or users).
IV Preliminary budget forecast (max € 950,000 funding from STW/DHF) including contribution from users
(overall and per centre): max ½ A4
Letters
1.
Position of applicant and co-applicant(s),
2.
Collaboration (or not) with national research programmes
3.
Statement of intent from possible users (part A)
Preproposal call 2015 earlier recognition of cardiovascular disease
Appendix
Curriculum Vitae
Provide the following information of the Applicant and the Principal Investigators/co-applicant(s)
Follow this format for each person. DO NOT EXCEED 1 A4 (per CV).
NAME
DATE OF BIRTH
POSITION TITLE
EDUCATION/TRAINING (Master, PhD, Clinical Specialization … only mention Institution, Degree, Year,
Field)
A. Positions and Honors
1. Positions and Employment
2. Other Experience and Professional Memberships
3. Honors and awards
B. Publications
1. Number of peer reviewed publications: 1) total, 2) as first author and 3) as second last and last author
2. Best 10 selected international peer reviewed publications, relevant for this proposal
3. Best 10 selected non-scientific publications, e.g. policy documents, guidelines or newspaper articles
etc.
C. Research (Support) (over the last 10 years)
1. Ongoing Research Support
2. Completed Research Support
D. Activities on knowledge management and utilisation (IP, translation of results for the public,
participation of patients in the research, etc.)